• Tel. 900 101 549
  • +34 93 546 01 35
  • Facebook IOR
  • Twitter IOR
  • LinkedIn IOR
  • Hospital Universitari Dexeus
  • Centro Médico Teknon
  • Hospital Universitari General de Cataluña
  • Hospital Universitari Sagrat Cor

ONCOLOGY UPDATE

Find out what's new in cancer research and treatment

MAKE A SELECTION TO ADJUST RESULTS
TO YOUR AREA OF INTEREST

ABOUT ONCOLOGY ABOUT IOR

02/02/2017

Identificación de las fusiones de ALK, ROS1 y RET mediante un ensayo multiplexado basado en ARNm en muestras de tejido parafinado de pacientes con cáncer de pulmón de célula no pequeña avanzado

PRESSGaceta Médica

LABELS Personalized treatment · Multiplex analysis · Lung cancer ·

Investigadores expertos del Laboratorio de IOR particpan en un estudio para valida la utilidad de la plataforma nCounter - tecnología ya implantada en el laboratorio - para realizar test multiplexados de transcritos de fusión (ARNm) mediante perfiles digitales directos o tecnología 'counting'. Esta tecnología de vanguardia ya está disponible para la realización de pruebas genéticas en el laboratorio.

+

21/11/2016

The IOR Laboratory signs an agreement with Laboratorio Echevarne to promote liquid biopsy

PRESSPress release

LABELS Liquid biopsy · Personalized treatment ·

Liquid biopsies allow oncologists to monitor treatment response in real time by analyzing a blood sample.

[Read more]

28/09/2016

Dr. Rosell and the IOR team to lead the lung cancer unit at Hospital Quirón Teknon

PRESSPress release

LABELS

Teknon becomes the fourth hospital from the Quirónsalud Group – joining Dexeus, Sagrat Cor and General de Catalunya – to incorporate the precision oncology services offered by IOR.

[Read more]

14/09/2016

Understanding the mechanisms of immunotherapy in lung cancer

PRESSVideo

LABELS Immunotherapy · Lung cancer ·

Dr. Rafael Rosell discusses the promise of immunotherapy for the treatment of lung cancer at Future Horizons in Lung Cancer 2016.

+

12/09/2016

Too affordable: how can we overcome the drug repurposing paradox?

PRESSCancer World

LABELS Repurposing drugs · Drug development ·

Looking for anticancer activity among off-patent drugs that are already approved to treat other conditions might seem a sensible way to speed up access to affordable new therapy options. Linda Geddes asks how such a strategy can work in practice, when the drugs are so cheap but the cost of approval is so high. Feat. Dr. Niki Karachaliou, Head of Medical Oncology, IOR Sagrat Cor.

+